Amgen clears new 2026 high, shares extend biotech sector gains
Published on 06/25/2026 at 19:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 19:33.
Amgen Inc. (US0311621009) trades on Nasdaq on Thursday around the upper end of this week's range, with the shares recently quoted near 358 dollars according to intraday data. The biotech heavyweight sits in the S&P 500 and Nasdaq-100, anchoring its role in the US large-cap healthcare cohort.
What the latest trading data shows
Intraday quote data from a real-time feed put Amgen shares at about 358.86 dollars at 09:54 Eastern time on June 25, corresponding to a gain of roughly 2.1 percent versus the previous close, underlining a marked positive tone in early trade. A consolidated quote snapshot lists the same timestamp and price for ticker AMGN.
In parallel, retail-focused platforms show Amgen changing hands in the mid-350 dollar area during the current session, with an intraday trading range roughly between 348 and 353 dollars reported as of the latest update, suggesting moderate volatility rather than outsized swings. One large US brokerage quote page highlights a session high near 353.42 dollars and a low around 348 dollars.
Sector backdrop and recent news flow
Amgen operates in the biotechnology segment, grouped under the MED - BIOMED/GENE industry on Nasdaq, where valuations and sentiment have recently been influenced by drug-pricing debates, patent litigation and regulatory scrutiny of specific therapies. A broad market data overview lists Amgen in the medical sector with a recent closing price of about 351.64 dollars on June 24 and extended-hours indications in the mid-340s.
The legal backdrop for Amgen has turned more complex in June after a Delaware jury found that the company and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding damages in the region of 20.2 million US dollars, which legal commentators frame as a material but not existential risk. Coverage on MarketScreener referencing Reuters summarizes the verdict and the potential for further litigation over antibody-related patents.
Background and price data on Amgen
Further news, regulatory filings and historical charts on the Amgen shares are bundled on the ad-hoc-news topic page and the company’s investor relations site.
The product behind the stock
Amgen’s business centers on biopharmaceuticals targeting serious illnesses, with key marketed products including the osteoporosis therapy Prolia (denosumab), the cholesterol-lowering agent Repatha (evolocumab) and the anti-inflammatory drug Enbrel (etanercept), among others. The company generates revenue primarily from the sale of these biologic medicines across North America, Europe and selected emerging markets.
Where the stock trades today
The Amgen shares (US0311621009) trade on Nasdaq on 2026-06-25 at around 358.86 US dollars as of 09:54 Eastern time.
Key data on the Amgen shares
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 09:54): 358.86 US dollars
- Market cap: about 190.7 billion US dollars (as of 2026-06-25)
- Sector / industry: Biotechnology / Biopharmaceuticals
- Index membership: S&P 500, NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable at the time of publication but may change without notice.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
